RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 HCV—Infected Patients with Compensated Cirrhosis Benefit from 12-Week, Once-Daily, Oral Combination of LDV and SOF
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 48
SP 21
OP 21
DO 10.1177/155989771448016
UL http://mdc.sagepub.com/content/14/48/21.abstract
AB The once-daily, oral, 12-week regimen using a single tablet combination of sofosbuvir (SOF; 400 mg) and ledipasvir (LDV; 90 mg) with or without ribavirin produces high sustained virologic response 12 weeks after conclusion of treatment in hepatitis C virus (HCV)-infected patients with compensated cirrhosis. This article discussed a study comprised of pooled data from the LONESTAR, ELECTRON and ELECTRON-2, ION-1 and ION-2, and SIRIUS trials.